Masitinib, the lead experimental medicine being developed by AB Science, can modulate the activity of different cell types known to be involved in inflammation and nerve degeneration in amyotrophic lateral sclerosis (ALS), according to results from a preclinical study. The findings were discussed in a presentation, titled “Post-paralysis treatment with…
Search results for:
Mesenchymal stem cells (MSCs) taken from the bone marrow of patients with amyotrophic lateral sclerosis (ALS) show an ability to control inflammation much like that seen in healthy people, but they respond differently and can be influenced by nearby pro-inflammatory molecules called cytokines, a…
News
Studying Epigenetic Changes Could Lead to New ALS Treatments and Biomarkers, Researchers Suggest
A specific type of genetic alteration — known as epigenetic changes — observed in patients with amyotrophic lateral sclerosis (ALS) may lead to novel treatments and diagnostic tools, according to a review study. The study, “Epigenetics in amyotrophic lateral sclerosis: a role for histone post-translational modifications…
News
New Prognosis Model Predicts Risk of Respiratory Insufficiency or Death in ALS Patients, Study Says
Scientists created a new prognosis model to predict the risk of respiratory insufficiency or death within six months of follow-up in patients with amyotrophic lateral sclerosis (ALS). The study, “Development of a prognostic model of respiratory insufficiency or death in amyotrophic lateral sclerosis,” was published in the…
On June 21, bicyclists will set out to make a three-day, 270-mile journey to raise funds for the ALS Therapy Development Institute. The Tri-State Trek expedition begins at Boston College in Chestnut Hill, Massachusetts, and ends in Greenwich, Connecticut. Proceeds go to the institute to advance its research into…
Newly diagnosed amyotrophic lateral sclerosis (ALS) patients often experience poor sleep quality due to symptoms of depression and difficulty turning in bed, a patient survey shows. The study, “Poor Sleep Quality in Patients With Amyotrophic Lateral Sclerosis at the Time of Diagnosis,” was published in the Journal…
UniQure is developing an experimental gene therapy for amyotrophic lateral sclerosis (ALS) using its proprietary, next-generation gene-silencing platform called miQure. ALS is a neurodegenerative disease characterized by the progressive loss of motor neurons — the nerve cells that control movement. ALS is progressive, meaning that symptoms worsen over…
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that affects motor neurons, the nerve cells responsible for controlling movement. In about 10% of cases, ALS is familial, meaning the disease does or did affect more than one person in the same family. Most patients, in contrast, have…
About 90% of cases of amyotrophic lateral sclerosis (ALS) — the progressive neurological disorder associated with the loss of motor neurons, the nerve cells that control movement — occur in patients with no family history of the disease. These cases are known as sporadic ALS, and occur randomly.
The U.S. Food and Drug Administration approved MediciNova’s plans for a pivotal Phase 2b/3 clinical trial that will explore the potential of ibudilast (MN-166) in patients with amyotrophic lateral sclerosis (ALS). Pending the success of the trial, the company hopes the collected clinical data will support the…